European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · 2011
Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Battaglia Teresa, De Grandis Elisa, Mirabelli-Badenier Marisol, Boeri Luca, Morcaldi Guido, Barabino Paola, Intra Chiara, Naselli Francesca, Pistoia Vito, Veneselli Edvige, Conte Massimo
Аннотация
We report the 1 year follow-up of 3 children affected by non-paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS) resistant to conventional therapies (steroids, ACTH and intravenous immunoglobulins) who were treated with an anti CD20 monoclonal antibody (rituximab). Treatment response was recorded on the basis of an international score at 0, 3, 6, 9 and 12 months. Despite the long disease duration and the numerous previously administered treatments, all patients underwent rapid and persistent neurological recovery following rituximab administration, thus suggesting a potential role of this drug even in pre-treated patients.
Предметные рубрики MeSH
Adrenocorticotropic HormoneAnti-Inflammatory AgentsAntibodies, Monoclonal, Murine-DerivedAtaxiaChild Behavior DisordersDexamethasoneDrug ResistanceElectroencephalographyGait Disorders, NeurologicHumansImmunoglobulins, IntravenousInfantMagnetic Resonance ImagingMaleOpsoclonus-Myoclonus SyndromePrednisoneRituximabSpeech DisordersTreatment OutcomeTremorVirus Diseases